

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs-Europe Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/IEB294A7082MEN.html

Date: May 2018

Pages: 144

Price: US\$ 3,480.00 (Single User License)

ID: IEB294A7082MEN

Abstracts

Report Summary

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2017, and development forecast 2018-2023

Main market players of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in

Europe, with company and product introduction, position in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market

Market status and development trend of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by types and applications

Cost and profit status of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and marketing status

Market growth drivers and challenges

The report segments the Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market as:

Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):



Germany
United Kingdom
France
Italy
Spain
Benelux
Russia

Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Preface

Eluxadoline

Alosetron

Rifaximin

Loperamide

Diphenoxylate + Atropine

Dicyclomine and Hyoscyamine

Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Others

Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Players Segment Analysis (Company and Product introduction, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharmaceuticals

Actavis

Pfizer

GlaxoSmithKline

Salix Pharmaceuticals Ltd

AstraZenenca



In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS

- 1.1 Definition of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in This Report
- 1.2 Commercial Types of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
 - 1.2.1 Preface
 - 1.2.2 Eluxadoline
 - 1.2.3 Alosetron
 - 1.2.4 Rifaximin
- 1.2.5 Loperamide
- 1.2.6 Diphenoxylate + Atropine
- 1.2.7 Dicyclomine and Hyoscyamine
- 1.3 Downstream Application of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
- 1.5 Market Status and Trend of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2023
- 1.5.1 EMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Trend 2013-2023
- 1.5.2 Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Regions
- 2.2.1 Consumption Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Regions
- 2.2.2 Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Regions
- 2.3 Market Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Regions
- 2.3.1 Market Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in



Europe 2013-2017

- 2.3.2 Market Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in Middle East 2013-2017
- 2.3.3 Market Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA 2018-2023
- 2.4.1 Market Development Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
- 3.1.1 Consumption Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Types
- 3.1.2 Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry in Europe
- 4.2.2 Demand Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry in Africa



4.3 Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Major Players
- 6.2 Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in EMEA by Major Players
- 6.3 Basic Information of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Players
- 6.3.1 Headquarters Location and Established Time of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Players
- 6.3.2 Employees and Revenue Level of Irritable Bowel Syndrome with Diarrhea (IBS-
- D) Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Astellas Pharmaceuticals
 - 7.1.1 Company profile
 - 7.1.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
- 7.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
- 7.2 Actavis
- 7.2.1 Company profile
- 7.2.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product



- 7.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Actavis
- 7.3 Pfizer
- 7.3.1 Company profile
- 7.3.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
- 7.3.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.4 GlaxoSmithKline
 - 7.4.1 Company profile
- 7.4.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
- 7.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.5 Salix Pharmaceuticals Ltd
 - 7.5.1 Company profile
 - 7.5.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
- 7.5.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
- 7.6 AstraZenenca
 - 7.6.1 Company profile
 - 7.6.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
- 7.6.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of AstraZenenca

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS

- 8.1 Industry Chain of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS

- 9.1 Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
- 9.2 Raw Materials Cost Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
- 9.3 Labor Cost Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
- 9.4 Manufacturing Expenses Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-
- D) Drugs



CHAPTER 10 MARKETING STATUS ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs-Europe Market Status and Trend

Report 2013-2023

Product link: https://marketpublishers.com/r/IEB294A7082MEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/IEB294A7082MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



